| 05/11 | TRANSCRIPT : Ascelia Pharma AB, Q1 2022 Earnings Call, May 11, 2022 | CI |
| 05/11 | QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals | AQ |
| 05/11 | Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/10 | Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver.. | AQ |
| 05/10 | Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is N.. | CI |
| 05/05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 | AQ |
| 05/05 | Ascelia Pharma AB Announces Resignation of Bo Jesper Hansen as Board Member | CI |
| 04/11 | Ascelia Pharma publishes Annual Report for 2021 | AQ |
| 04/05 | Notice of annual general meeting in ascelia pharma ab | AQ |
| 04/01 | CFO Kristian Borbos to leave Ascelia Pharma | AQ |
| 03/31 | Number of shares and votes in Ascelia Pharma AB | AQ |
| 03/31 | HC ANDERSEN CAPITAL : Release of new Ascelia Pharma investment case | AQ |
| 03/22 | New independent market research says 84% US healthcare professionals likely to use Orvi.. | AQ |
| 03/11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study | AQ |
| 03/11 | Ascelia Pharma AB Successfully Completes Orviglance Hepatic Impairment Study | CI |
| 03/07 | Ascelia Pharma suspends clinical activities in Russia | AQ |
| 03/07 | Ascelia Pharma Suspends Clinical Activities in Russia | CI |
| 03/02 | Issue and repurchase of series C shares for share saving program | AQ |
| 02/15 | Results from Orviglance comparison study to gadolinium accepted for oral presentation a.. | AQ |
| 02/10 | TRANSCRIPT : Ascelia Pharma AB, 2021 Earnings Call, Feb 10, 2022 | CI |
| 02/10 | QUARTERLY REPORT Q4 2021 : Strong data for Orviglance vs. a gadolinium contrast agent | AQ |
| 02/10 | Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended D.. | CI |
| 2021 | Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial | AQ |
| 2021 | Ascelia Pharma AB Receives FDA Acceptance of IND Application for Oncoral Clinical Trial | CI |
| 2021 | Results from Orviglance comparison study to gadolinium presented at RSNA 2021 | AQ |
| 2021 | Ascelia Pharma AB Announces Results from Orviglance comparison study to gadolinium pres.. | CI |
| 2021 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB | AQ |
| 2021 | TRANSCRIPT : Ascelia Pharma AB, Nine Months 2021 Earnings Call, Nov 04, 2021 | CI |
| 2021 | QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration | AQ |
| 2021 | Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended .. | CI |
| 2021 | ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed | AQ |
| 2021 | Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully | CI |
| 2021 | ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the .. | AQ |
| 2021 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the.. | CI |
| 2021 | ASCELIA PHARMA AB(OM : ACE) added to S&P Global BMI Index | CI |
| 2021 | Certain Ordinary Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending .. | CI |
| 2021 | TRANSCRIPT : Ascelia Pharma AB, H1 2021 Earnings Call, Aug 19, 2021 | CI |
| 2021 | QUARTERLY REPORT Q2 2021 : Preparing Oncoral for the next level | AQ |
| 2021 | Ascelia Pharma AB publ Announces Earnings Results for the Second Quarter Ended June 30,.. | CI |
| 2021 | ASCELIA PHARMA : Covid-19 extends recruitment period of SPARKLE study | AQ |
| 2021 | Ascelia Pharma AB Announces That the Continued Global Impact of the Covid-19 Pandemic C.. | CI |
| 2021 | ASCELIA PHARMA : Abstract for Orviglance comparison study to gadolinium accepted at the wo.. | AQ |
| 2021 | Ascelia Pharma AB Announces Abstract for Orviglance Comparison Study to Gadolinium Acce.. | CI |
| 2021 | ASCELIA PHARMA : receives conditional FDA acceptance for brand name Orviglance | AQ |
| 2021 | Ascelia Pharma AB Receives Conditional U.S. Food and Drug Administration Acceptance for.. | CI |
| 2021 | TRANSCRIPT : Ascelia Pharma AB, Q1 2021 Earnings Call, May 12, 2021 | CI |
| 2021 | QUARTERLY REPORT Q1 2021 : US office opened in preparation of launch | AQ |
| 2021 | Ascelia Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2.. | CI |
| 2021 | ASCELIA PHARMA : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 20.. | AQ |
| 2021 | ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB | AQ |
| 2021 | ASCELIA PHARMA AB : publishes prospectus regarding admission to trading of newly issued sh.. | AQ |
| 2021 | ASCELIA PHARMA : Bulletin from the extraordinary general meeting in Ascelia Pharma AB | AQ |
| 2021 | ASCELIA PHARMA : Issue and repurchase of series C shares for share saving program | AQ |
| 2021 | ASCELIA PHARMA : Notice of annual general meeting in ascelia pharma ab | AQ |
| 2021 | ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB | AQ |
| 2021 | ASCELIA PHARMA : publishes Annual Report for 2020 | AQ |
| 2021 | ASCELIA PHARMA : Notice of extraordinary general meeting in Ascelia Pharma | AQ |
| 2021 | ASCELIA PHARMA : has carried out a directed new share issue raising SEK 200 million | AQ |
| 2021 | ASCELIA PHARMA : intends to carry out a directed new share issue | AQ |
| 2021 | ASCELIA PHARMA : opens US office in preparation for Mangoral launch | AQ |
| 2021 | Ascelia Pharma AB Opens US Office in Preparation for Mangoral Launch | CI |
| 2021 | TRANSCRIPT : Ascelia Pharma AB, 2020 Earnings Call, Feb 16, 2021 | CI |
| 2021 | QUARTERLY REPORT Q4 2020 : Mangoral shows high diagnostic value in new study | AQ |
| 2021 | Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter of 2020 | CI |
| 2021 | ASCELIA PHARMA : Information regarding transfer of shares in Ascelia Pharma AB from CMC SP.. | AQ |
| 2021 | ASCELIA PHARMA : presents clinical development plan for Oncoral as a novel chemotherapy | AQ |
| 2021 | Ascelia Pharma AB Presents Clinical Development Plan for Oncoral as a Novel Chemotherap.. | CI |
| 2020 | ASCELIA PHARMA : gets US patent for second generation Mangoral | AQ |
| 2020 | Ascelia Pharma Gets US Patent for Second Generation Mangoral | CI |
| 2020 | ASCELIA PHARMA : New study shows Mangoral's lesion visualization as effective as gadoliniu.. | AQ |
| 2020 | Ascelia Pharma AB Announces New Study Shows Mangoral's Lesion Visualization as Effectiv.. | CI |
| 2020 | TRANSCRIPT : Ascelia Pharma AB, Nine Months 2020 Earnings Call, Nov 05, 2020 | CI |
| 2020 | QUARTERLY REPORT Q3-2020 : Raised market estimate for Mangoral and preparing for market la.. | AQ |
| 2020 | Ascelia Pharma AB Announces Earnings Results for the Third Quarter of 2020 | CI |
| 2020 | ASCELIA PHARMA : EMA confirms Mangoral eligible for the centralized regulatory procedure i.. | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
